Results 111 to 120 of about 23,498 (195)

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study. [PDF]

Front Neurol
Huygens S, Versteegh M, Berg-Hansen P, Bjelland SH, Holmøy T, Torkildsen Ø.   +5 more
europepmc   +1 more source

Progressive multifocal leukoencephalopathy - a diagnostic guide for the clinical neurologist. [PDF]

Front Neurol
Jia DT.
europepmc   +1 more source

A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis. [PDF]

Eur J Neurol
Maersk-Moller C, Pontieri L, Stilund MLM, Christensen JR, Storr LK, Hansen V, Schäfer J, Weglewski A, Romani KQ, Jensen HB, Illes Z, Papp V, Sejbaek T, Poulsen MB, Kant M, Torring CW, Sellebjerg F, Magyari M, DMSG Group.   +18 more
europepmc   +1 more source

Is it time to target no evident disease activity (NEDA) in multiple sclerosis? [PDF]

, 2015
Banwell, Bermel, Cohen, Cohen, Coles, Coles, Comi, Confavreux, Dobson, Erbayat Altay, Giovannoni, Giovannoni, Giovannoni, Hartung, Havrdova, Kappos, Leray, Levesque, Miller, Rio, Scalfari, Solomon, Sormani, Sormani, Tuohy, Zivadinov   +25 more
core   +1 more source

CD56^brightNK cells are negatively associated with antibody response to vaccination in people with multiple sclerosis on B-cell-depleting therapy. [PDF]

Clin Transl Immunology
Perkins GB, Hope CM, Chai CS, Tunbridge MJ, Sterling S, Webb K, Yap J, Yeow AEL, Masavuli MG, Scaffidi J, Zuiani JD, Akerman A, Aggarwal A, Milogiannakis V, Roberts MB, Hurtado PR, Turville S, Grubor-Bauk B, Barry SC, Ravindran J, Coates PT, Hissaria P.   +21 more
europepmc   +1 more source

Managing reactivation of multiple sclerosis during treatment with natalizumab. [PDF]

Mult Scler
Lizak N, Sharmin S, Horáková D, Havrdova EK, Eichau S, van der Walt A, Butzkueven H, Lechner-Scott J, Buzzard K, Skibina O, Gerlach O, Prat A, Girard M, Duquette P, Alroughani R, Patti F, Grand'Maison F, Sá MJ, Aguera-Morales E, Hodgkinson S, Grammond P, Kuhle J, Yamout B, Khoury SJ, Ozakbas S, Csepany T, John N, Laureys G, Terzi M, Amato MP, Boz C, Al-Asmi A, Cartechini E, Gouider R, Mrabet S, Roos I, Kalincik T.   +36 more
europepmc   +1 more source

Clinical relevance and predictors of anti-natalizumab antibodies in multiple sclerosis: A real-world retrospective cohort study. [PDF]

Mult Scler J Exp Transl Clin
Levy M, Beigneux Y, Roux T, Mossad M, Ricigliano V, Senant M, Papeix C, Stankoff B, Louapre C, Maillart E, Lazzarotto A.   +10 more
europepmc   +1 more source

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study [PDF]

, 2016
Alessia di Sapio, Antonio Bertolotto, Francesca Sperli, Manuela Matta, Marco Capobianco, Maria Malentacchi, Marianna Lo Re, Simona Malucchi   +7 more
core   +1 more source

Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials. [PDF]

Mult Scler
Strijbis E, Mostert J, D'Haeseleer M, Moral E, Brieva Ruiz L, Comtois J, Killestein J, Repovic P, McPherson T, Cutter G, Koch M.   +10 more
europepmc   +1 more source

No association between the wearing-off effect and α4-integrin receptor saturation in natalizumab treated patients with relapsing-remitting multiple sclerosis. [PDF]

Neurotherapeutics
Freeman SA, Rual C, Biotti D, Lepetit M, Le Berre J, Ferrara K, Treiner E, Ciron J.   +7 more
europepmc   +1 more source